Poging GOUD - Vrij
China is overplaying its hand with its rare-earth choke-offs
Mint Chennai
|January 12, 2026
Its export curbs aimed at Japan could prove counterproductive
To a hammer, every problem is a nail. If your most potent means of geopolitical leverage is threatening supplies of high-strength magnets, rare-earth elements will always be the solution.
That's the latest approach Beijing is taking in its dispute with Tokyo. Exports of all items with potential military applications to Japan will be immediately banned, China's ministry of commerce said on Tuesday.
The most obvious victim of this threat will be rare-earth magnets made with the elements neodymium and praseodymium, and increasingly spiced up with rarer samarium, dysprosium and terbium. They're used everywhere from charging cables to the switch-gear in wind turbines to motors powering electric vehicles, missile-guidance systems and aircraft flaps.
There's just one problem: Few countries are better prepared against China threatening their rare-earth supplies than Japan. Thanks to similar threats in 2010, it has spent years diversifying its supply chains and building up stockpiles for precisely this sort of eventuality.
While China produces about 80% of the world's neodymium magnets, Japan manufactures about half the remainder, according to UBS SuMi TRUST Wealth Management—levels far above its own roughly 5% share of global manufacturing.
Dit verhaal komt uit de January 12, 2026-editie van Mint Chennai.
Abonneer u op Magzter GOLD voor toegang tot duizenden zorgvuldig samengestelde premiumverhalen en meer dan 9000 tijdschriften en kranten.
Bent u al abonnee? Aanmelden
MEER VERHALEN VAN Mint Chennai
Mint Chennai
Lenskart wants artificial intelligence to test your eyes
It expects AI-enabled eye testing to become the default foundational layer of eyecare delivery
3 mins
January 13, 2026
Mint Chennai
More companies to take a hit as labour codes debut
Reworked gratuity and leave encashments spell additional expenses for India Inc
2 mins
January 13, 2026
Mint Chennai
HC lifts ban on Zydus cancer biosimilar till patent expiry
In a relief for Zydus Lifesciences, a division bench of the Delhi High Court on Monday allowed the drugmaker to sell and market its biosimilar of the anticancer drug nivolumab in India, citing public interest.
2 mins
January 13, 2026
Mint Chennai
Trump’s investigation of Powell is also a warning to the next Fed chair
The criminal investigation into Federal Reserve Chair Jerome Powell isn’t ultimately about the Fed’s headquarters, or Powell, or even interest rates.
3 mins
January 13, 2026
Mint Chennai
States flag Almont-Kid syrup as tests find contaminants
Syrup found ‘Not of Standard Quality’ with contaminants like toxic ethylene glycol
1 mins
January 13, 2026
Mint Chennai
India at 100: Our choices today will define the next two decades
India's 2047 ambition is not guaranteed but achievable if we address all the potential pitfalls along our development path
4 mins
January 13, 2026
Mint Chennai
Now, inheritance works without probate—but why it still matters
Heirs can now act on a valid will without court cases, easing delays and unlocking assets in undisputed cases
6 mins
January 13, 2026
Mint Chennai
Why VCs have a new deep-tech playbook
where fundraising starts to drag,\" said Chand.
1 min
January 13, 2026
Mint Chennai
TCS, HCLTech deliver Q3 revenue surprise
clearer.
2 mins
January 13, 2026
Mint Chennai
US productivity is rising and it risks warping monetary policy
America's neutral rate ought to be going up but will the Fed listen?
3 mins
January 13, 2026
Listen
Translate
Change font size
